MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
Clinical trials for MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS explained in plain language.
Never miss a new study
Get alerted when new MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS trials appear
Sign up with your email to follow new studies for MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New psoriasis drug goes Head-to-Head with established treatment
Disease control CompletedThis study tested a new drug called Bmab 1200 against an already approved drug, Stelara, to see if it works as well for controlling moderate to severe plaque psoriasis. About 384 adults with this skin condition received one of the two drugs for a year, and researchers measured ho…
Matched conditions: MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
Phase: PHASE3 • Sponsor: Biocon Biologics UK Ltd • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New drug shows promise for Near-Total skin clearance in psoriasis
Disease control CompletedThis study tested an investigational drug called bimekizumab in adults with moderate to severe plaque psoriasis. It was a large, late-stage trial comparing the drug to a placebo to see how well it cleared skin and reduced symptoms like itch and pain. The main goal was to see if p…
Matched conditions: MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New injection shows promise for clearing severe psoriasis
Disease control CompletedThis study tested whether a new injectable medication called JS005 can safely and effectively treat moderate to severe plaque psoriasis. It involved 747 adults who received either JS005 at one of two doses or a placebo injection. The main goal was to see how many patients achieve…
Matched conditions: MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
Phase: PHASE3 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New drug trial aims for completely clear skin in psoriasis patients
Disease control CompletedThis study tested if a new drug called bimekizumab works better than an existing drug, secukinumab, for adults with moderate to severe plaque psoriasis. It involved 743 participants and measured how clear their skin became over 48 weeks. The main goal was to see if bimekizumab co…
Matched conditions: MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
3-Year psoriasis drug study shows promising Long-Term skin clearance
Disease control CompletedThis study followed 1,353 adults with moderate to severe plaque psoriasis for up to 3 years to check the long-term safety and effectiveness of the drug bimekizumab. Participants who had completed earlier bimekizumab studies continued receiving the medication in this open-label ex…
Matched conditions: MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New hope for kids with severe skin condition
Disease control CompletedThis study observed 42 children and teenagers in China with moderate to severe plaque psoriasis who were prescribed the medication Cosentyx. It aimed to collect real-world safety information and see how well the drug worked to clear or nearly clear their skin over one year. The s…
Matched conditions: MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
New drug shows promise for clearing severe skin plaques
Disease control CompletedThis study tested an investigational drug called bimekizumab for adults with moderate to severe plaque psoriasis. It compared bimekizumab against a placebo and an existing treatment to see how well it cleared skin plaques and reduced symptoms like itch and pain. The main goal was…
Matched conditions: MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Mar 09, 2026 14:25 UTC
-
New psoriasis drug shows promise for dramatic skin clearance
Disease control CompletedThis study tested whether an injectable drug called bimekizumab is better than a placebo at clearing skin in adults with moderate to severe plaque psoriasis. It involved 133 Chinese participants who received injections for 16 weeks. Researchers measured how much the psoriasis imp…
Matched conditions: MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Mar 02, 2026 15:23 UTC